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time before switching were examined. Descriptive and Chi-
Square statistical analyses were conducted to determine if dif-
ferences existed among the three cohorts. RESULTS: A total of
1242 patients were analyzed: 490 (39.4%) inﬂiximab plus MTX;
607 (48.9%) etanercept plus MTX; and 145 (11.7%) adali-
mumab plus MTX. Over two-thirds of the patients were female
and the mean age was 50.0 years. The Charlson Co-morbidity
Index and disease staging were similar among the three cohorts.
During the 12 months follow-up, 39 patients (7.9%) in the inﬂix-
imab plus MTX cohort switched compared to 72 patients
(11.9%) in the etanercept group and 23 patients (15.9%) in the
adalimumab group. Chi-Square analyses indicated the differ-
ences were statistically signiﬁcant (p < 0.05) as compared to the
inﬂiximab plus MTX cohort. The inﬂiximab group had an
average time of 195.9 days before switching, compared to 183.1
days in the etanercept group, and 165.3 in the adalimumab
group; this was not statistically signiﬁcant. CONCLUSION: The
rate of switching and time before switching are important mea-
sures of the effectiveness of RA treatment in real world practice.
This study found that inﬂiximab plus MTX is associated with a
longer time before switching and a signiﬁcantly lower switching
rate, as compared to the other anti-TNFs. Further studies are
needed to evaluate the impact of switching on clinical and eco-
nomic outcomes.
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OBJECTIVES: To evaluate persistence of anti-TNF treatment
among rheumatoid arthritis (RA) patients utilizing a managed
care database. METHODS: A retrospective study utilizing the
PharMetrics managed care claims database was conducted. The
ﬁrst anti-TNF (inﬂiximab, etanercept, or adalimumab) encounter
(index date) among RA patients between January 1, 2001 and
January 1, 2004 was identiﬁed. Patients were required to have a
minimum of 12-months of continuous plan eligibility prior to
and following their index biologic date. Three mutually exclu-
sive cohorts were developed based on their index biologic; inﬂix-
imab plus methotrexate (MTX); etanercept plus MTX; and
adalimumab plus MTX. Anti-TNF persistence (%) was deﬁned
as the number of days between the ﬁrst biologic prescription and
their last biologic encounter, divided by 365 and multiplied by
100. Both univariate and multivariate analyses were applied to
determine if differences in persistence existed between the three
cohorts. RESULTS: A total of 1242 patients were analyzed con-
sisting of 490 (39.4%) inﬂiximab plus MTX; 607 (48.9%) etan-
ercept plus MTX; and 145 (11.7%) adalimumab plus MTX.
Over two-thirds of the patients were female and the mean age
was 50.0 years. The Charlson Co-morbidity Index and disease
staging were consistent among the three cohorts. The inﬂiximab
plus MTX cohort was more persistent [78.0% than the other 2
cohorts (etanercept plus MTX 73.6% and adalimumab plus
MTX 70.8%)] and was statistically signiﬁcant (p < 0.05). After
adjusting for potential confounding variables (age, gender,
Charlson co-morbidity index and disease severity), inﬂiximab
patients had 5.4% more persistence than etanercept (p < 0.01),
and 7.0% more than the adalimumab group (p < 0.05). Etaner-
cept patients were more persistent than the adalimumab group,
however, the difference was not signiﬁcant (p > 0.05). CON-
CLUSION: These results indicate that patients on inﬂiximab plus
MTX are more persistent with anti-TNF therapy, compared to
other anti-TNFs. Further studies are needed to evaluate the
impact of persistence on clinical outcomes.
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OBJECTIVES: To compare dosing stability and dose changes,
through a retrospective database analysis, for rheumatoid arthri-
tis (RA) patients taking inﬂiximab over ﬁve years. METHODS:
We utilized medical and pharmacy claims data from the Medstat
MarketScan database. The sample consisted of “new starts” for
inﬂiximab users in the commercial and Medicare population: (a)
with a diagnosis of Rheumatoid Arthritis (RA) (ICD-9 714.xx),
(b) who had at least three documented administrations of inﬂix-
imab between 1999 and 2005, (c) who had no prescription
history for any TNF blocker for a 6 month period prior to the
index infusion, and, (d) who were continuously enrolled for a
minimum of 365 days after their index infusion. We examined
the proportion of inﬂiximab users who showed an increase,
decrease, or no change in dose over time in both groups.
RESULTS: Medicare inﬂiximab users (n = 729) were older (mean
age = 73 years) with higher co-morbid scores (mean score = 9.71)
than commercial users (n = 1903, mean age = 50 years, mean
score = 3.83). Following the index infusion, 30.4% of commer-
cial and 17.7% of Medicare users showed no change; 24.6% of
commercial and 43.1% of Medicare users showed a decrease;
and 44.9% of commercial and 39.2% of Medicare members
showed an increase in their dose. For the ﬁve-year period, the
total average dose change between the ﬁrst and last infusion was
24 mg for the Medicare group and 44 mg for the commercial
group. Medicare members also had a lower starting dose than
commercial members (328 mg vs. 366 mg). CONCLUSION:
This study demonstrates that there is dose stability in RA
patients treated with inﬂiximab, as the dose changed on average,
by less than 3% per year over the ﬁve-year period. Further
research is needed to evaluate the impact of dose changes on clin-
ical and economic outcomes.
PAR19
ARTHRITIS AND HEALTH-RELATED QUALITY OF LIFE
AMONG ADULTS IN OHIO
Kim SH
Florida International University, Miami, FL, USA
OBJECTIVES: Clinicians have long observed a link between
physical pain and a compromised quality of life among the clin-
ical population. However, little is known about the association
between arthritis and the quality of life in the general popula-
tion. This study is designed to identify the impact of arthritis on
the quality of life among adults. METHODS: The Behavioral
Risk Factor Surveillance System (BRFSS) is a state-based,
random-digit-dialed telephone survey of the non-institutional-
ized U.S. population aged 18 years and older. The Ohio BRFSS-
2005 survey, containing 7498 adults was analyzed. As a measure
of Health–Related Quality of Life, the number of “unhealthy
days” during the preceding 30 days was surveyed. All informa-
tion was self-reported. RESULTS: Approximately the same pro-
portion of adults in different age groups experienced at least one
physical unhealthy day in the general adult population (35.6%,
18–44 years old; 37.3%, 45–64 years old; 36.3%, 65 years old
